MGMT Promoter Hypermethylation and K-Ras, PTEN and TP53 Mutations in Tamoxifen-Exposed and Non-Exposed Endometrial Cancer Cases

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2014.263
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Expression and Promoter Hypermethylation Status of MGMT, RASSF1A in Gastric Cancer

World Journal of Cancer Research
2014English

K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

ISRN Molecular Biology
2012English

Role of Human PTEN and TP53 Sequence Mutations in the Etiology of Breast Cancer in Saudi Patients

Pakistan Journal of Biological Sciences
AgronomyCrop Science
2020English

MLH1 Promoter Hypermethylation in Uterine Carcinosarcoma Rarely Coexists With TP53 Mutation

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2019English

PTEN Expression in Benign Human Endometrial Tissue and Cancer in Relation to Endometrial Cancer Risk Factors

Cancer Causes and Control
Cancer ResearchOncology
2015English

Tumor Protein P53 and K-Ras Gene Mutations in Peruvian Patients With Gallbladder Cancer

Asian Pacific Journal of Cancer Prevention
2019English

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

Clinical Cancer Research
Cancer ResearchOncology
2008English

TP53 and MDM2 Polymorphisms and the Risk of Endometrial Cancer in Postmenopausal Women

Medical Oncology
MedicineCancer ResearchOncologyHematology
2014English

TP53 Codon 72 Polymorphism Is Associated With FGFR3 and RAS Mutation in Non-Muscle-Invasive Bladder Cancer

PLoS ONE
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy